Yelena Ginzburg, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the efficacy and side effects associated with the use of rusfertide in polycythemia vera (PV), explaining that current studies have reported high efficacy rates and low rates of toxicity. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
